FEDERAL COURT OF AUSTRALIA
Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd [2019] FCA 230
File numbers: NSD 121 of 2012
NSD 837 of 2015Judge: YATES J Date of judgment: 27 February 2019 Catchwords: PRACTICE AND PROCEDURE – proceedings to enforce undertakings as to damages given in patent infringement proceedings – where several enforcement proceedings commenced – where allegations in one set of enforcement proceedings admitted but corresponding allegations in another set of enforcement proceedings denied – whether inconsistent allegations can be pleaded – whether pleading of denials is an abuse of the Court’s process – whether pleading of denials should be struck out Legislation: Federal Court of Australia Act 1976 (Cth) s 4
Federal Court Rules 2011, rr 16.06, 16.21(1)(f), 22.07, 30.11
National Health Act 1953 (Cth)
Cases cited: Batistatos v Roads and Traffic Authority of New South Wales [2006] HCA 27; (2006) 226 CLR 256
Issitch v Worrell (2000) 172 ALR 586
J C Decaux Pty Ltd v Adhsel Street Furniture Pty Ltd [2000] FCA 1118; (2000) 178 ALR 339
Laws v Australian Broadcasting Tribunal (1990) 170 CLR 70
Stohl Aviation v Electrum Finance Pty Ltd (1984) 5 FCR 187
Surfing Hardware International Holdings Pty Ltd v McCausland [2008] FCA 1522; (2008) 171 FCR 533
Date of hearing: 10 December 2018 Registry: New South Wales Division: General Division National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Category: Catchwords Number of paragraphs: 41 Counsel for the Applicants/ Appellants: Mr J Sheahan QC
Mr J HuttonSolicitor for the Applicants/ Appellants: Allens Counsel for the Respondent The Respondent did not appear Counsel for the Commonwealth of Australia: Mr P J Brereton SC
Mr P Knowles
Ms F RoughleySolicitor for the Commonwealth of Australia: Corrs Chambers Westgarth ORDERS
NSD 121 of 2012
NSD 837 of 2015BETWEEN: OTSUKA PHARMACEUTICAL CO., LTD
First Applicant / First Appellant
BRISTOL-MYERS SQUIBB COMPANY
Second Applicant / Second Appellant
AND: GENERIC HEALTH PTY LTD (ACN 110 617 859)
Respondent
COMMONWEALTH OF AUSTRALIA
Other
JUDGE:
YATES J
DATE OF ORDER:
27 FEBRUARY 2019
THE COURT ORDERS THAT:
1.The interlocutory application filed on 16 November 2018 by the Commonwealth of Australia (the Commonwealth) be dismissed.
2.The Commonwealth pay the costs of Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company of and incidental to the interlocutory application.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
YATES J:
INTRODUCTION
The Commonwealth of Australia (the Commonwealth) applies to strike out paragraphs 78, 79, 80 and 82 of the Points of Defence which have been filed by Otsuka Pharmaceutical Co., Ltd (Otsuka) and Bristol-Myers Squibb Company (BMS) (together, Otsuka/BMS) in response to Amended Points of Claim filed by the Commonwealth in proceedings commenced by the Commonwealth to enforce undertakings as to damages given by Otsuka/BMS.
The undertakings were given by Otsuka/BMS in patent infringement proceedings commenced in…
Keep reading for free
Create a free CaseChat account to read Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2019] FCA 230
- Decision Date
CaseChat Overview and Summary
The court considered whether inconsistent pleadings in different proceedings are permissible under the Federal Court Rules. The Commonwealth argued that inconsistent pleadings are prohibited by r 16.06 of the Rules, while the defendants argued that the rule does not prohibit inconsistent pleadings as long as they are pleaded as alternatives. The court found that r 16.06 is not a prohibition on pleading inconsistent allegations, but rather a rule ensuring clarity in pleading. The court also found that a party cannot plead inconsistent facts where one set of facts must be known to be false. However, the court did not find that the defendants had pleaded inconsistent facts with knowledge that they were false.
The court also considered whether pleading inconsistent allegations in separate proceedings is an abuse of the Court’s process. The defendants argued that the several proceedings were separate and distinct, and that the rules do not speak across all proceedings involving a particular party. The court agreed with the defendants and found that the separate and distinct nature of the proceedings meant that the rules did not prohibit pleading inconsistent allegations. The court also noted that each interlocutory application was an “incidental proceeding” in connection with the primary proceeding and the appeal proceeding, respectively.
The court dismissed the Commonwealth’s application to strike out the inconsistent pleadings and ordered that the Commonwealth pay the costs of Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company. The court found that the defendants had a sufficient basis to plead the inconsistent allegations and that the pleading of the inconsistent allegations was not an abuse of the Court’s process. The court also found that the separate and distinct nature of the several proceedings meant that the rules did not prohibit pleading inconsistent allegations.
Orders
Orders of the court
1. The interlocutory application filed on 16 November 2018 by the Commonwealth of Australia (the Commonwealth) be dismissed.
2. The Commonwealth pay the costs of Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company of and incidental to the interlocutory application.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.